Acetyl- l -carnitine increases artemin level and prevents neurotrophic factor alterations during neuropathy

Abstract Damages to the nervous system are the primarily cause of neuropathy and chronic pain. Current pharmacological treatments for neuropathic pain are not able to prevent or revert morphological and molecular consequences of tissue injury. On the other hand, many neurotrophins, like nerve growth...

Full description

Saved in:
Bibliographic Details
Published inNeuroscience Vol. 167; no. 4; pp. 1168 - 1174
Main Authors Vivoli, E, Di Cesare Mannelli, L, Salvicchi, A, Bartolini, A, Koverech, A, Nicolai, R, Benatti, P, Ghelardini, C
Format Journal Article
LanguageEnglish
Published Amsterdam Elsevier 02.06.2010
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Abstract Damages to the nervous system are the primarily cause of neuropathy and chronic pain. Current pharmacological treatments for neuropathic pain are not able to prevent or revert morphological and molecular consequences of tissue injury. On the other hand, many neurotrophins, like nerve growth factor (NGF), paired off restorative effects with hyperalgesia. Interestingly, the glial cell line–derived neurotrophic factors GDNF and Artemin (ARTN) seem to support neuron survival and to normalize abnormal pain behaviour. In the present research protein levels of NGF, GDNF and ARTN were evaluated in a rat model of peripheral neuropathy, the chronic constriction injury (CCI). NGF was increased by CCI in the ipsilateral dorsal root ganglia (DRG), in the spinal cord and in the periaqueductal grey matter (PAG). On the contrary, ARTN was decreased bilaterally in DRG, spinal cord and PAG. GDNF levels decreased in ipsilateral DRG, whereas the constriction did not modify its expression in the central nervous system districts. Repeated treatments with the antihyperalgesic and neuroregenerative compound acetyl- l -carnitine (ALCAR; 100 mgkg−1 i.p. twice daily for 15 days) was able to prevent the increase of NGF levels. In conditions of pain relief ALCAR normalized peripheral and central alterations of GDNF and ARTN levels. Characteristically, sham animals that underwent the same ALCAR treatment, showed increased levels of ARTN both in the DRG and in the spinal cord. These data offer a new point of view on the mechanism of the antihyperalgesic as well as the neuroprotective effect of ALCAR.
AbstractList Damages to the nervous system are the primarily cause of neuropathy and chronic pain. Current pharmacological treatments for neuropathic pain are not able to prevent or revert morphological and molecular consequences of tissue injury. On the other hand, many neurotrophins, like nerve growth factor (NGF), paired off restorative effects with hyperalgesia. Interestingly, the glial cell line-derived neurotrophic factors GDNF and Artemin (ARTN) seem to support neuron survival and to normalize abnormal pain behaviour. In the present research protein levels of NGF, GDNF and ARTN were evaluated in a rat model of peripheral neuropathy, the chronic constriction injury (CCI). NGF was increased by CCI in the ipsilateral dorsal root ganglia (DRG), in the spinal cord and in the periaqueductal grey matter (PAG). On the contrary, ARTN was decreased bilaterally in DRG, spinal cord and PAG. GDNF levels decreased in ipsilateral DRG, whereas the constriction did not modify its expression in the central nervous system districts. Repeated treatments with the antihyperalgesic and neuroregenerative compound acetyl-l-carnitine (ALCAR; 100 mgkga1 i.p. twice daily for 15 days) was able to prevent the increase of NGF levels. In conditions of pain relief ALCAR normalized peripheral and central alterations of GDNF and ARTN levels. Characteristically, sham animals that underwent the same ALCAR treatment, showed increased levels of ARTN both in the DRG and in the spinal cord. These data offer a new point of view on the mechanism of the antihyperalgesic as well as the neuroprotective effect of ALCAR.
Damages to the nervous system are the primarily cause of neuropathy and chronic pain. Current pharmacological treatments for neuropathic pain are not able to prevent or revert morphological and molecular consequences of tissue injury. On the other hand, many neurotrophins, like nerve growth factor (NGF), paired off restorative effects with hyperalgesia. Interestingly, the glial cell line-derived neurotrophic factors GDNF and Artemin (ARTN) seem to support neuron survival and to normalize abnormal pain behaviour. In the present research protein levels of NGF, GDNF and ARTN were evaluated in a rat model of peripheral neuropathy, the chronic constriction injury (CCI). NGF was increased by CCI in the ipsilateral dorsal root ganglia (DRG), in the spinal cord and in the periaqueductal grey matter (PAG). On the contrary, ARTN was decreased bilaterally in DRG, spinal cord and PAG. GDNF levels decreased in ipsilateral DRG, whereas the constriction did not modify its expression in the central nervous system districts. Repeated treatments with the antihyperalgesic and neuroregenerative compound acetyl-l-carnitine (ALCAR; 100 mgkg(-1) i.p. twice daily for 15 days) was able to prevent the increase of NGF levels. In conditions of pain relief ALCAR normalized peripheral and central alterations of GDNF and ARTN levels. Characteristically, sham animals that underwent the same ALCAR treatment, showed increased levels of ARTN both in the DRG and in the spinal cord. These data offer a new point of view on the mechanism of the antihyperalgesic as well as the neuroprotective effect of ALCAR.
Damages to the nervous system are the primarily cause of neuropathy and chronic pain. Current pharmacological treatments for neuropathic pain are not able to prevent or revert morphological and molecular consequences of tissue injury. On the other hand, many neurotrophins, like nerve growth factor (NGF), paired off restorative effects with hyperalgesia. Interestingly, the glial cell line-derived neurotrophic factors GDNF and Artemin (ARTN) seem to support neuron survival and to normalize abnormal pain behaviour. In the present research protein levels of NGF, GDNF and ARTN were evaluated in a rat model of peripheral neuropathy, the chronic constriction injury (CCI). NGF was increased by CCI in the ipsilateral dorsal root ganglia (DRG), in the spinal cord and in the periaqueductal grey matter (PAG). On the contrary, ARTN was decreased bilaterally in DRG, spinal cord and PAG. GDNF levels decreased in ipsilateral DRG, whereas the constriction did not modify its expression in the central nervous system districts. Repeated treatments with the antihyperalgesic and neuroregenerative compound acetyl-l-carnitine (ALCAR; 100 mgkg(-1) i.p. twice daily for 15 days) was able to prevent the increase of NGF levels. In conditions of pain relief ALCAR normalized peripheral and central alterations of GDNF and ARTN levels. Characteristically, sham animals that underwent the same ALCAR treatment, showed increased levels of ARTN both in the DRG and in the spinal cord. These data offer a new point of view on the mechanism of the antihyperalgesic as well as the neuroprotective effect of ALCAR.Damages to the nervous system are the primarily cause of neuropathy and chronic pain. Current pharmacological treatments for neuropathic pain are not able to prevent or revert morphological and molecular consequences of tissue injury. On the other hand, many neurotrophins, like nerve growth factor (NGF), paired off restorative effects with hyperalgesia. Interestingly, the glial cell line-derived neurotrophic factors GDNF and Artemin (ARTN) seem to support neuron survival and to normalize abnormal pain behaviour. In the present research protein levels of NGF, GDNF and ARTN were evaluated in a rat model of peripheral neuropathy, the chronic constriction injury (CCI). NGF was increased by CCI in the ipsilateral dorsal root ganglia (DRG), in the spinal cord and in the periaqueductal grey matter (PAG). On the contrary, ARTN was decreased bilaterally in DRG, spinal cord and PAG. GDNF levels decreased in ipsilateral DRG, whereas the constriction did not modify its expression in the central nervous system districts. Repeated treatments with the antihyperalgesic and neuroregenerative compound acetyl-l-carnitine (ALCAR; 100 mgkg(-1) i.p. twice daily for 15 days) was able to prevent the increase of NGF levels. In conditions of pain relief ALCAR normalized peripheral and central alterations of GDNF and ARTN levels. Characteristically, sham animals that underwent the same ALCAR treatment, showed increased levels of ARTN both in the DRG and in the spinal cord. These data offer a new point of view on the mechanism of the antihyperalgesic as well as the neuroprotective effect of ALCAR.
Abstract Damages to the nervous system are the primarily cause of neuropathy and chronic pain. Current pharmacological treatments for neuropathic pain are not able to prevent or revert morphological and molecular consequences of tissue injury. On the other hand, many neurotrophins, like nerve growth factor (NGF), paired off restorative effects with hyperalgesia. Interestingly, the glial cell line–derived neurotrophic factors GDNF and Artemin (ARTN) seem to support neuron survival and to normalize abnormal pain behaviour. In the present research protein levels of NGF, GDNF and ARTN were evaluated in a rat model of peripheral neuropathy, the chronic constriction injury (CCI). NGF was increased by CCI in the ipsilateral dorsal root ganglia (DRG), in the spinal cord and in the periaqueductal grey matter (PAG). On the contrary, ARTN was decreased bilaterally in DRG, spinal cord and PAG. GDNF levels decreased in ipsilateral DRG, whereas the constriction did not modify its expression in the central nervous system districts. Repeated treatments with the antihyperalgesic and neuroregenerative compound acetyl- l -carnitine (ALCAR; 100 mgkg−1 i.p. twice daily for 15 days) was able to prevent the increase of NGF levels. In conditions of pain relief ALCAR normalized peripheral and central alterations of GDNF and ARTN levels. Characteristically, sham animals that underwent the same ALCAR treatment, showed increased levels of ARTN both in the DRG and in the spinal cord. These data offer a new point of view on the mechanism of the antihyperalgesic as well as the neuroprotective effect of ALCAR.
Author Di Cesare Mannelli, L
Ghelardini, C
Benatti, P
Vivoli, E
Nicolai, R
Salvicchi, A
Bartolini, A
Koverech, A
Author_xml – sequence: 1
  fullname: Vivoli, E
– sequence: 2
  fullname: Di Cesare Mannelli, L
– sequence: 3
  fullname: Salvicchi, A
– sequence: 4
  fullname: Bartolini, A
– sequence: 5
  fullname: Koverech, A
– sequence: 6
  fullname: Nicolai, R
– sequence: 7
  fullname: Benatti, P
– sequence: 8
  fullname: Ghelardini, C
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23087260$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/20302919$$D View this record in MEDLINE/PubMed
BookMark eNqFkU1r3DAQhkVJaTZp_0IRhdKTN_qwJe-lEELbFAI9NDmLsTRutNHKriQH9t9HyW7pMYNgBPNoNPO-Z-QkThEJ-cTZmjOuLrbriEuasvUYLa4FqwUm14zrN2TFey0b3bXtCVkxyVTTdkKckrOct6xG18p35FTUitjwzYo8XFos-9DQQBsLKfriI1IfbULImCmkgjsfacBHDBSio3Oq11gyfRmipGm-95aOYMuUKISCCYqfYqZuST7-OWAzlPv9e_J2hJDxwzGfk7vv326vrpubXz9-Xl3eNFb2bWla1wFsuEAQ3aCcskI5GDnvONej0oPaDKN1joEUTMHAUaC2XHOncexEXfCcfDn0ndP0d8FczM5niyFAxGnJpu-UrkexV0ktpZId7_tKfjySy7BDZ-bkd5D25p-SFfh8BCBbCGOCaH3-z0nWa_Hy5dcDh1WBR4_J2OCjr08ecI95Oy0pVnEMN1kYZn4_e_hsIa_mSdW38gkZEZ8v
CODEN NRSCDN
CitedBy_id crossref_primary_10_1007_s00213_011_2326_0
crossref_primary_10_1016_j_douler_2013_01_007
crossref_primary_10_1016_j_neulet_2018_08_051
crossref_primary_10_1007_s40263_013_0132_4
crossref_primary_10_4103_1673_5374_230297
crossref_primary_10_1016_j_neuroscience_2014_11_025
crossref_primary_10_1007_s11011_021_00773_w
crossref_primary_10_3390_ijms241914841
crossref_primary_10_3390_neurosci5030018
crossref_primary_10_1016_j_bbrc_2014_01_082
crossref_primary_10_3389_fendo_2021_806819
crossref_primary_10_2174_1570159X15666170915143217
crossref_primary_10_1371_journal_pone_0037621
crossref_primary_10_1097_MOG_0b013e3283505a3b
crossref_primary_10_1111_andr_13187
crossref_primary_10_1111_papr_12403
crossref_primary_10_1586_14737175_2013_814930
crossref_primary_10_1111_j_1464_410X_2011_10705_x
crossref_primary_10_3390_molecules200610657
crossref_primary_10_1021_acsbiomaterials_7b00655
crossref_primary_10_1016_j_expneurol_2010_11_005
crossref_primary_10_1186_1744_8069_7_16
crossref_primary_10_1016_j_brainres_2011_01_002
crossref_primary_10_1007_s11011_023_01206_6
crossref_primary_10_1016_j_eurger_2017_01_002
crossref_primary_10_1016_j_mam_2011_10_007
crossref_primary_10_1097_01_j_pain_0000460339_23976_12
crossref_primary_10_3389_fnut_2022_853058
crossref_primary_10_1080_00207454_2022_2107515
crossref_primary_10_1155_2013_328797
crossref_primary_10_1016_j_neulet_2017_07_059
crossref_primary_10_1016_j_phrs_2021_105874
ContentType Journal Article
Copyright IBRO
2015 INIST-CNRS
Copyright 2010 IBRO. Published by Elsevier Ltd. All rights reserved.
Copyright_xml – notice: IBRO
– notice: 2015 INIST-CNRS
– notice: Copyright 2010 IBRO. Published by Elsevier Ltd. All rights reserved.
DBID IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
7TK
DOI 10.1016/j.neuroscience.2010.03.017
DatabaseName Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
Neurosciences Abstracts
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
Neurosciences Abstracts
DatabaseTitleList Neurosciences Abstracts
MEDLINE
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Anatomy & Physiology
EISSN 1873-7544
EndPage 1174
ExternalDocumentID 20302919
23087260
1_s2_0_S0306452210003684
Genre Retracted Publication
Journal Article
GroupedDBID ---
--K
--M
-DZ
-~X
.1-
.55
.FO
.GJ
.~1
0R~
123
1B1
1P~
1RT
1~.
1~5
29N
4.4
457
4G.
53G
5RE
5VS
7-5
71M
8P~
9JM
AABNK
AACTN
AAEDT
AAEDW
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQXK
AAXKI
AAXLA
AAXUO
ABCQJ
ABFNM
ABFRF
ABJNI
ABLJU
ABMAC
ABTEW
ABXDB
ACDAQ
ACGFO
ACGFS
ACIUM
ACRLP
ADBBV
ADEZE
ADMUD
AEBSH
AEFWE
AEKER
AENEX
AEVXI
AFCTW
AFJKZ
AFKWA
AFRHN
AFTJW
AFXIZ
AGHFR
AGUBO
AGWIK
AGYEJ
AHHHB
AIEXJ
AIKHN
AITUG
AJOXV
AJUYK
AKRWK
ALMA_UNASSIGNED_HOLDINGS
AMFUW
AMRAJ
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
CS3
DU5
EBS
EFJIC
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-2
G-Q
GBLVA
HMQ
HVGLF
HZ~
IHE
J1W
KOM
L7B
M2V
M41
MO0
MOBAO
N9A
O-L
O9-
OAUVE
OP~
OZT
P-8
P-9
P2P
PC.
Q38
R2-
RIG
ROL
RPZ
SCC
SDF
SDG
SDP
SES
SEW
SNS
SPCBC
SSN
SSZ
T5K
UNMZH
WUQ
X7M
YYP
Z5R
ZGI
ZXP
~G-
08R
AADPK
AAIAV
AAUGY
ABPIF
ABPTK
ABYKQ
AJBFU
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
7TK
ID FETCH-LOGICAL-c384t-4d5aa912ea25b6d6c26daf115117f67b69bfcdd0a3206ab1e2e7c171d7ef52543
ISSN 0306-4522
1873-7544
IngestDate Fri Oct 25 04:51:48 EDT 2024
Sat Oct 26 02:16:53 EDT 2024
Tue Oct 29 09:20:18 EDT 2024
Sun Oct 22 16:08:02 EDT 2023
Tue Oct 15 22:55:54 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords pain
acetyl- l-carnitine
periaqueductal grey matter
artemin
dorsal root ganglia
CCI
chronic constriction injury
NGF
glial cell line-derived neurotrophic factor
GDNF
ARTN
nerve growth factor
PAG
neurorestoration
DRG
ALCAR
Neurotrophic factor
Pain
Glial cell line derived neurotrophic factor
Nerve growth factor
Language English
License CC BY 4.0
Copyright 2010 IBRO. Published by Elsevier Ltd. All rights reserved.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c384t-4d5aa912ea25b6d6c26daf115117f67b69bfcdd0a3206ab1e2e7c171d7ef52543
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Correction/Retraction-3
ObjectType-Article-2
ObjectType-Feature-1
PMID 20302919
PQID 733635188
PQPubID 23479
PageCount 7
ParticipantIDs proquest_miscellaneous_856756760
proquest_miscellaneous_733635188
pubmed_primary_20302919
pascalfrancis_primary_23087260
elsevier_clinicalkeyesjournals_1_s2_0_S0306452210003684
PublicationCentury 2000
PublicationDate 2010-06-02
PublicationDateYYYYMMDD 2010-06-02
PublicationDate_xml – month: 06
  year: 2010
  text: 2010-06-02
  day: 02
PublicationDecade 2010
PublicationPlace Amsterdam
PublicationPlace_xml – name: Amsterdam
– name: United States
PublicationTitle Neuroscience
PublicationTitleAlternate Neuroscience
PublicationYear 2010
Publisher Elsevier
Publisher_xml – name: Elsevier
References 39332810 - Neuroscience. 2024 Sep 24:S0306-4522(24)00494-9. doi: 10.1016/j.neuroscience.2024.09.041
References_xml
SSID ssj0000543
Score 2.2206645
SecondaryResourceType retracted_publication
Snippet Abstract Damages to the nervous system are the primarily cause of neuropathy and chronic pain. Current pharmacological treatments for neuropathic pain are not...
Damages to the nervous system are the primarily cause of neuropathy and chronic pain. Current pharmacological treatments for neuropathic pain are not able to...
SourceID proquest
pubmed
pascalfrancis
elsevier
SourceType Aggregation Database
Index Database
Publisher
StartPage 1168
SubjectTerms Acetyl-L-carnitine
Acetylcarnitine - pharmacology
Analgesics - pharmacology
Animals
Biological and medical sciences
Constriction, Pathologic - complications
Fundamental and applied biological sciences. Psychology
Ganglia, Spinal - metabolism
Male
Nerve Growth Factors - metabolism
Nerve Tissue Proteins - metabolism
Neurology
Neuroprotective Agents - pharmacology
Pain - etiology
Pain - metabolism
Pain Threshold
Periaqueductal Gray - metabolism
Peripheral Nervous System Diseases - etiology
Peripheral Nervous System Diseases - metabolism
Rats
Rats, Sprague-Dawley
Sciatic Nerve - injuries
Spinal Cord - metabolism
Vertebrates: nervous system and sense organs
Title Acetyl- l -carnitine increases artemin level and prevents neurotrophic factor alterations during neuropathy
URI https://www.clinicalkey.es/playcontent/1-s2.0-S0306452210003684
https://www.ncbi.nlm.nih.gov/pubmed/20302919
https://www.proquest.com/docview/733635188
https://search.proquest.com/docview/856756760
Volume 167
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Li9swEBbp9lIope32kT4WHUovwcGS38ew3WUpaXpoUnITsixRL6kTYqewPfS3d0a2Y4fd0MfFBOEoJvNprBnNfB8h72SikectcIxWxvEDYxwYMY7yeeSmxsjAyrd9moVXC__jMlgOBqZXtbSr0rH6eWdfyf9YFcbArtgl-w-W3U8KA_AZ7AtXsDBc_8rGE6Wrm5UzdRTmN6rcMoDgNrDUJbIXIXHIaIVlQS0fwA_b0GZJLKvtevMtV43izsgemzd1cU3vor0NJYsPjn5nHQPmHhRfc_By-UFjw4d8dK5LrCtDHWak_ex6HDCjI1fgo5SVFO7nU7cVqgj1RpuMBB6mYx1zz4nGkecgsV79jrljrPW8tRJHAzG_50cZq8V2bjn4OtdwPe6xfeqmQM8bu3Ub6CGr9uyzuFxMp2J-sZzfI_c5OCQs_Rv_6kqBYNtqGzHaZ2zJaW0d4LFfOti9PNzIEtaUqcVQjkcrdtcyf0weNeEGndTYeUIGunhKTieFrNbfb-h7aguA7cnKKclvw4nu4UQbOFELJwpwoi2caB9OtIYT7cGJ1nCiHZyekcXlxfz8ymmUOBzlxX7l-FkgZcK4ljxIwyxUPMykgWCCsciEURomqVFZ5kqPu6FMmeY6UixiWaRNgHQLz8lJsS70S0I96arIB8dg0tTnWZbEAffx676JTWbiIYnav1W0zcHwOtNls-5KwUTJhSu-YLSLegDMkirF_pCcHVhBbGq-FsGR9RLi9iGhrVkEOFE8GZOFXu9KgZygHlITHr8lDiC0DiOc5UVt0W5-eBKesOTVn-d_TR50K-YNOam2O_0WdrVVemYh-RsCxKsv
link.rule.ids 315,783,787,27938,27939
linkProvider Elsevier
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Acetyl-L-carnitine+increases+artemin+level+and+prevents+neurotrophic+factor+alterations+during+neuropathy&rft.jtitle=Neuroscience&rft.au=Vivoli%2C+E&rft.au=Di+Cesare+Mannelli%2C+L&rft.au=Salvicchi%2C+A&rft.au=Bartolini%2C+A&rft.date=2010-06-02&rft.issn=1873-7544&rft.eissn=1873-7544&rft.volume=167&rft.issue=4&rft.spage=1168&rft_id=info:doi/10.1016%2Fj.neuroscience.2010.03.017&rft.externalDBID=NO_FULL_TEXT
thumbnail_m http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F03064522%2FS0306452210X00094%2Fcov150h.gif